GlassScriptPhysician profile
Eliscer Guzman
NPI 1679560833
$242,737.21
in general payments reported to CMS, 2019-2025
49 companies · $27K in 2025
The $27K reported for 2025 was more than what 97% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $43K · 2020: $35K · 2021: $26K · 2022: $43K · 2023: $29K · 2024: $39K · 2025: $27K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $74K · Food and Beverage: $19K · Consulting Fee: $2,800 · Education: $17.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $74,134.75 |
| Food and Beverage | $18,826.69 |
| Consulting Fee | $2,800.00 |
| Education | $17.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $98,875.26 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $54,912.38 | 2019-2025 | Lokelma, Farxiga, Wainua |
| Amgen INC. | $33,704.74 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $13,629.08 | 2019-2025 | |
| Lilly USA, LLC | $9,149.12 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Esperion Therapeutics, INC. | $6,952.82 | 2020-2025 | Nexletol |
| E.R. Squibb & Sons, L.L.C. | $4,707.72 | 2019-2025 | Camzyos, Eliquis |
| Amarin Pharma, INC. | $3,764.98 | 2019-2022 | |
| Cvrx, INC. | $2,848.64 | 2023 | Barostim Neo System |
| Novo Nordisk INC | $2,496.82 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $2,179.68 | 2019-2023 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $1,311.64 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $965.18 | 2019-2025 | Verquvo, Steglatro, Capvaxive |
| Medtronic, INC. | $837.70 | 2021-2025 | Hawkone, In.Pact Admiral, Abre |
| Shockwave Medical, INC | $771.44 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eliscer Guzman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.